MedTech & Life Sciences Newsletter March 2026
MedTech & Life Sciences Newsletter – March 2026
Royer Cooper Cohen Braunfeld’s MedTech & Life Sciences team closely tracks the regulatory, transactional, and intellectual property developments shaping the medical device, pharmaceutical, and broader life sciences sectors. Our newsletter highlights recent regulatory updates, M&A trends, valuation considerations, and patent developments that may affect companies operating in these highly regulated industries.
In this edition, we review key updates from the U.S. FDA and EU regulators, emerging AI and digital health regulatory frameworks, current MedTech and BioPharma M&A activity, and notable intellectual property developments impacting regulated products.
Download the full newsletter below to explore these developments and their potential implications for companies, investors, and innovators in the MedTech and Life Sciences space. Sign up for our newsletter and other publications here.
